首页> 外文会议>International Conference on Bioinformatics and Systems Biology >Prediction of Drug Application Optimization Based on RBC Dynamics in Maintenance Chemotherapy of Acute Lymphoblastic Leukemia Maintenance
【24h】

Prediction of Drug Application Optimization Based on RBC Dynamics in Maintenance Chemotherapy of Acute Lymphoblastic Leukemia Maintenance

机译:基于RBC动力学的急性淋巴细胞白血病维持化疗的药物应用优化预测。

获取原文

摘要

Acute lymphoid leukemia (ALL), a common childhood cancer has a high rate of disease relapse problem. In clinic it is generally treated with three stages-intensive chemotherapy, consolidation stage and finally a maintenance therapy. The final stage therapy is the most important part of the regime that last for approximately two years and targeted to remove residual leukemic cell population. To achieve long term leukemia free survival detection of residual leukemic cell in bone marrow level is essential. Again in the treatment of leukemia removal of leukemic cell is not the major issue rather sustenance of the normal cell population is the biggest challenge. A delay ordinary differential equation (DODE) based model is developed for chemotherapeutic dosing optimization so that residual leukemic cell population is removed along with the maintenance of normal cell population. With the chemotherapeutic maintenance therapy in ALL patients' data, here we show that the model can aptly be fitted with the real life clinical scenario.
机译:急性淋巴白血病(ALL)是一种常见的儿童癌症,具有很高的疾病复发率。在临床上,通常通过强化化疗,巩固期和最后的维持治疗三个阶段进行治疗。最终阶段的治疗是该治疗方案中最重要的部分,持续了大约两年时间,旨在去除残留的白血病细胞群。为了实现长期无白血病生存,检测骨髓水平中残留的白血病细胞至关重要。再次,在白血病的治疗中,去除白血病细胞不是主要问题,而维持正常细胞群体是最大的挑战。建立了基于延迟常微分方程(DODE)的模型,用于化学疗法的剂量优化,以便在维持正常细胞群的同时去除残留的白血病细胞群。通过所有患者数据中的化学疗法维持治疗,我们在这里表明该模型可以适当地适应现实生活中的临床情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号